Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published data in Nature Communications demonstrating a novel mechanism for degrading BRD9, a key cancer target, using its proprietary Targeted Glue small molecule degrader.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
The Company's innovative approach combines the benefits of earlier technologies while overcoming their limitations, offering a promising prospect for rational drug design.
Author's summary: Amphista Therapeutics publishes novel cancer target degradation mechanism.
More News
- Global PAH data shows rising cases and risk factors in elderly
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- First Duel Night Abyss Figure Is Based on Psyche
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- Global PAH data shows rising cases and risk factors in elderly
- Why hasn’t Zohran Mamdani taken a position on the ballot proposals?
- Johnson’s “Protecting Chicago” budget proposes nearly $500M in tax hikes
- Exploring the Flawlessness of Nature - Blood: River of Red Gold
- MCU: Jeremy Allen White Responds to Popular X-Men Fan Casting
- Horse grazing in The Villages - Villages-News.com